Cannabidiol Increases Psychotropic Effects and Plasma Concentrations of Δ9-Tetrahydrocannabinol Without Improving Its Analgesic Properties.
Clinical pharmacology and therapeutics November 1, 2024 Andriy A Gorbenko, Jules A A C Heuberger, Linda E Klumpers et al. 17 citations
A clinical trial tested whether cannabidiol (CBD) can reduce the adverse effects of tetrahydrocannabinol (THC) and improve its tolerability as an analgesic. Healthy volunteers received THC alone or with different doses of CBD. Contrary to expectations, the highest CBD dose (450 mg) significantly increased THC's subjective, psychomotor, cognitive, and autonomous effects—for example, feeling high increased by 60.5%—and did not enhance pain relief. Lower CBD doses had no significant effect on THC's effects. CBD also increased blood levels of THC and its active metabolite. The findings do not support using CBD to reduce oral THC's adverse effects or to improve its analgesic properties.